Clinical trials: Retinal Disorders
Nonproliferative Diabetic Retinopathy
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy…
- Trial name
- TIME-2b (NCT03197870)
- Testing
- AKB-9778
- Where
- 53 sites in United States
- Volunteers
- 167 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Age-Related Macular Degeneration
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain…
- Trial name
- NCT05672121
- Testing
- KH631
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy
Adjunct Episcleral Brachytherapy for PCV
This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate…
- Trial name
- KILAUEA (NCT05251636)
- Testing
- Episcleral Brachytherapy, Aflibercept Injection
- Volunteers
- 159 people
- Sponsor
- Salutaris Medical Devices, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS patients experiencing their first episode of cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002432
- Testing
- Foscarnet sodium
- Where
- United States
- Sponsor
- Astra USA
Age-Related Maculopathy, Age-Related Maculopathies
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration
- Trial name
- NCT00877032
- Testing
- RN6G
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Pfizer
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in China.
- Conditions
- Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT06439576
- Testing
- Faricimab
- Where
- 41 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Hoffmann-La Roche
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Diffuse Diabetic Macular Edema
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.
- Trial name
- NCT00886808
- Testing
- iCo-007 Intravitreal Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- iCo Therapeutics Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03666923
- Testing
- THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Geographic Atrophy
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant.
- Trial name
- PRIMAvera (NCT04676854)
- Testing
- PRIMA Bionic Vision System
- Where
- 21 sites in France, Germany and 4 more
- Volunteers
- 38 people
- Sponsor
- Science Corporation
X-linked Retinoschisis
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 5 years of age with RS1-associated X-linked retinoschisis (XLRS).
- Trial name
- LIGHTHOUSE (NCT05878860)
- Testing
- ATSN-201
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 97 people
- Sponsor
- Atsena Therapeutics Inc.
Dry Macular Degeneration
Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration
This will be an open-label, non-randomized multi-center study of adipose stem cell (ASC) implantation. ASCs will be derived from the patient's adipose or fat.
- Trial name
- NCT02024269
- Testing
- Adipose Derived Stem Cells
- Where
- United States
- Sponsor
- Bioheart, Inc.
Age Related Macular Degeneration
Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients
Patients with AMD who are being or have been treated with eye injections of drugs known as anti-VEGF agents with either good or poor response will have DNA collected with check swabs for analysis.
- Trial name
- EVERGREEN (NCT01644513)
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Sequenom, Inc.
Macular Edema
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
- Trial name
- NCT02188173
- Testing
- dexamethasone 700 ㎍ intravitreal implant
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Allergan
Retinal Vein Occlusion
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
- Trial name
- NCT02387788
- Testing
- AKB-9778
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Aerpio Therapeutics
Geographic Atrophy
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate.
- Trial name
- ARCHER (NCT04656561)
- Testing
- ANX007
- Where
- 53 sites in United States, Australia and 1 more
- Volunteers
- 270 people
- Sponsor
- Annexon, Inc.
Cytomegalovirus Retinitis, HIV Infections
An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS
To evaluate the safety and tolerance of cidofovir (HPMPC) infusions in AIDS patients with relapsing cytomegalovirus (CMV) retinitis. To determine the time to retinitis progression in this patient population.
- Trial name
- NCT00002142
- Testing
- Cidofovir, Probenecid
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Diabetic Retinopathy, Diabetic Eye Problems
Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision…
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT03112005
- Testing
- Color fundus photography, Mydriatic Agent
- Where
- United States
- Volunteers
- 942 people
- Sponsor
- Eyenuk, Inc.
Retinitis Pigmentosa
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells.
- Trial name
- NCT05909488
- Testing
- 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Diabetes Mellitus, Diabetic Retinopathy
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
This study will evaluate the safety and efficacy of AG-014699 in diabetic patients
- Trial name
- NCT00457470
- Testing
- AG-014699
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.